Rare urinary cancer hits 6,000-7,000 yearly as UroGen starts clinician honors First honoree is Rutgers Cancer Institute's Dr. Saum Ghodoussipour. UroGen says the effort promotes guideline-based, kidney-sparing LG-UTUC care.

#URGN UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer

www.stocktitan.net/news/URGN/uro-gen-launch...

Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI UroGen (Nasdaq: URGN) announced publication in The Journal of Urology of Phase 3 ENVISION results for ZUSDURI (mitomycin) for recurrent low‑grade intermediate‑risk non‑muscle invasive bladder cancer.Key data: 24‑month event‑free probability 72.2% after three‑month complete response (CR rate 79.6%; 95% CI: 64%, 79%), median follow‑up 23.7 months, median duration of response not reached. Safety: common adverse reactions ≥10% and serious adverse reactions in 12% (urinary retention 0.8%, urethral stenosis 0.4%). ZUSDURI is the first FDA‑approved therapy for recurrent LG‑IR‑NMIBC.

#URGN Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI

www.stocktitan.net/news/URGN/journal-of-uro...

UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence UroGen (NASDAQ:URGN) applauded BCAN's New Faces of Bladder Cancer report, a national survey of more than 1,100 patients highlighting recurrence burden and procedural load.Key findings: nearly 80% fear recurrence (over 90% for patients under 50), women 86%, retained-bladder patients 87%, many report five or more cystoscopies and some report more than 15 procedures.

#URGN UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence

www.stocktitan.net/news/URGN/uro-gen-applau...

UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results UroGen (Nasdaq: URGN) reported full-year 2025 revenue of $109.8M, driven by ZUSDURI launch and JELMYTO sales, and announced the permanent J Code (J9282) effective Jan 1, 2026 to support reimbursement.The company closed an amended loan with Pharmakon providing a $200M initial tranche and an optional $50M tranche, reported 2025 net loss of $153.5M, and held $120.5M in cash and securities at year-end.

#URGN UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/URGN/uro-gen-announ...

UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors UroGen (Nasdaq: URGN) entered an amended senior secured term loan with funds managed by Pharmakon on Feb 26, 2026, providing up to $250 million in two tranches.The first tranche of $200 million funded at closing refinances an existing $125 million facility, sets a fixed 8.25% interest rate, allows a discretionary $50 million draw through June 30, 2027, has no financial covenants, and schedules repayment in four equal quarterly payments beginning Q1 2030.

#URGN UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors

www.stocktitan.net/news/URGN/uro-gen-announ...

ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC UroGen (Nasdaq: URGN) reported post‑hoc ENVISION Phase 3 analyses showing ZUSDURI (75 mg mitomycin intravesical) produced high complete response (CR) rates across EORTC recurrence score groups in recurrent LG‑IR‑NMIBC. Three‑month CRs were 83.9%, 81.2%, and 60.0% for EORTC scores 1–4, 5–9, and 10–17; majority of responders remained recurrence‑free at 24 months (Kaplan‑Meier estimates 67.4%–73.7%).

#URGN ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC

www.stocktitan.net/news/URGN/zusduritm-achi...

Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally | The Motley Fool A full exit after a monster rally says less about the company’s science and more about how disciplined funds lock in wins when portfolio math starts to matter.

#URGN #381585b0-f936-4743-9b64-ff2d9ae9a8d0 #coveragefilings

Origin | Interest | Match

JUST IN: ( NASDAQ: #URGN ) UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference

#URGN UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum

www.stocktitan.net/news/URGN/uro-gen-report...

Trade Alerts, Monday November 3, 2025 – Crystal Equity Research

Small-cap stocks in new uptrend according to ave directional index, Mon Nov 3rd - #URGN #MDXG #III #EVTV #BYSI #ADTN #PDS #MD #FRGE #CMRE - More: crystalequityresearch.com/trade-alerts... - #smallcap

Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026 UroGen (Nasdaq: URGN) announced that the Centers for Medicare and Medicaid Services assigned a permanent HCPCS Level II J Code J9282 for ZUSDURI (mitomycin) for intravesical solution, effective January 1, 2026.The code applies to billing in hospital outpatient departments and physician offices and is intended to standardize claims submission, simplify reimbursement processes for providers (subject to individual payor coverage policies), and reduce administrative barriers to patient access for the FDA‑approved treatment for recurrent low‑grade intermediate‑risk non‑muscle invasive bladder cancer.

#URGN Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026

www.stocktitan.net/news/URGN/centers-for-me...

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results UroGen Pharma (NASDAQ: URGN) announced Q2 2025 results and the launch of ZUSDURI™, marking its evolution into a multi-product uro-oncology company. JELMYTO® achieved net product sales of $24.2 million in Q2 2025, representing 11% year-over-year growth. The company reported a net loss of $49.9 million ($1.05 per share).Key highlights include the FDA approval of ZUSDURI for recurrent LG-IR-NMIBC treatment, with a $5 billion+ market opportunity. The company maintains $161.6 million in cash and equivalents, and reaffirms 2025 JELMYTO revenue guidance of $94-98 million. Operating expenses are expected to be $215-225 million for 2025.

#URGN UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/URGN/uro-gen-pharma...

UroGen Pharma Ltd. Faces Class Action: Key Deadlines and Implications for Investors UroGen Pharma Ltd. is currently involved in a class action lawsuit. Shareholders must register by July 28, 2025, to be eligible for potential recovery.

UroGen Pharma Ltd. Faces Class Action: Key Deadlines and Implications for Investors #USA #New_York #Class_Action #UroGen_Pharma #URGN

Investors Rally Against UroGen Pharma Following Securities Fraud Allegations in Major Class Action Lawsuit UroGen Pharma Ltd. faces a significant class action lawsuit for alleged securities violations. Investors are urged to seek representation by Levi & Korsinsky before the July 2025 deadline.

Investors Rally Against UroGen Pharma Following Securities Fraud Allegations in Major Class Action Lawsuit #United_States #New_York #Securities_Law #UroGen_Pharma #URGN

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! PM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #MSTR 56% OTM
2. #AMD 29% OTM
3. #NET 27% OTM
4. #URGN 21% OTM
5. #ADBE 21% OTM

#OptionFlow #OptionsTrading #Trading

JUST IN: ( NASDAQ: #URGN ) U.S. FDA Approves UroGen's ZUSDURI(TM) (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

A medical professional in a white lab coat holds a digital illustration of a human bladder, symbolizing advanced urological care, with the company name UroGen Pharma represented.

Big win for #URGN: The FDA has approved ZUSDURI, the first and only non-surgical treatment for recurrent low-grade bladder cancer. A major step forward for patients facing repeat surgeries.
#UroGenPharma
prismmarketview.com/urogen-soars...

UroGen Pharma Ltd. Shareholders Alert: Class Action Notice Issued by The Gross Law Firm Shareholders of UroGen Pharma Ltd. (URGN) who faced losses are urged to contact The Gross Law Firm regarding a pending class action lawsuit related to misleading statements.

UroGen Pharma Ltd. Shareholders Alert: Class Action Notice Issued by The Gross Law Firm #USA #New_York #Gross_Law_Firm #URGN #UroGen

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#INMB, #URGN, #CLSK, #NN, #ETOR

#OptionFlow #OptionsTrading #Trading

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! PM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #INMB 155% OTM
2. #URGN 80% OTM
3. #CLSK 41% OTM
4. #TSLA 38% OTM
5. #NN 38% OTM

#OptionFlow #OptionsTrading #Trading

Investors in UroGen Pharma are Under Investigation for Possible Securities Fraud Pomerantz Law Firm is investigating claims regarding potential securities fraud involving UroGen Pharma, amid significant stock price decline following FDA scrutiny.

Investors in UroGen Pharma are Under Investigation for Possible Securities Fraud #United_States #New_York #Pomerantz_Law_Firm #UroGen_Pharma #URGN

Latest ASCO 2025 Data: How 400 Cancer Patients Respond to JELMYTO Treatment in Groundbreaking Registry Study New real-world registry tracks JELMYTO outcomes in 400 upper tract cancer patients across 22 clinical sites. See comprehensive 3-year follow-up data insights.

#URGN UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer

www.stocktitan.net/news/URGN/uro-gen-presen...

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

Weekly Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #URGN 150% OTM
2. #WOLF 107% OTM
3. #WRD 87% OTM
4. #LQDA 66% OTM
5. #MSTR 62% OTM

#OptionFlow #OptionsTrading #Trading

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#WOLF, #URGN, #IRBT, #BYND, #SMR

#OptionFlow #OptionsTrading #Trading

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #WOLF 179% OTM
2. #URGN 150% OTM
3. #IRBT 71% OTM
4. #GME 48% OTM
5. #X 44% OTM

#OptionFlow #OptionsTrading #Trading

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#WOLF, #URGN, #IRBT, #X, #U

#OptionFlow #OptionsTrading #Trading

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

AM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #WOLF 179% OTM
2. #URGN 150% OTM
3. #IRBT 71% OTM
4. #GME 50% OTM
5. #X 43% OTM

#OptionFlow #OptionsTrading #Trading